<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>05400951001180</udiDi>
    <basicUdiDi>5400951FBFORTIIBT1B3</basicUdiDi>
    <tradeName>XLS Medical Pro 7</tradeName>
    <deviceName>FAT BINDER FORTE type 1</deviceName>
    <manufacturerName>Omega Pharma International NV</manufacturerName>
    <manufacturerSrn>BE-MF-000007210</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0402</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>CT28088</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-31T07:49:26.898Z</lastUpdated>
  </row>
  <row>
    <udiDi>05400951001197</udiDi>
    <basicUdiDi>5400951FBFORTIIBT2B5</basicUdiDi>
    <tradeName>XLS Medical Pro 7</tradeName>
    <deviceName>FAT BINDER FORTE type 2</deviceName>
    <manufacturerName>Omega Pharma International NV</manufacturerName>
    <manufacturerSrn>BE-MF-000007210</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0402</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>CT28089</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-07-31T07:42:28.862Z</lastUpdated>
  </row>
  <row>
    <udiDi>05400951001104</udiDi>
    <basicUdiDi>5400951FBFORTIIBT1B3</basicUdiDi>
    <tradeName>XLS Medical Pro 7 Kapseln</tradeName>
    <deviceName>FAT BINDER FORTE type 1</deviceName>
    <manufacturerName>Omega Pharma International NV</manufacturerName>
    <manufacturerSrn>BE-MF-000007210</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0402</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>CT30783</reference>
    <placedOnMarketCountry>Belgium</placedOnMarketCountry>
    <lastUpdated>2026-07-31T07:42:28.056Z</lastUpdated>
  </row>
  <row>
    <udiDi>05061009420010</udiDi>
    <basicUdiDi>506100942ES-CYT-102Z9</basicUdiDi>
    <tradeName>EndoSign® Cell collection device</tradeName>
    <deviceName>EndoSign® Cell collection device</deviceName>
    <manufacturerName>Cyted Ltd</manufacturerName>
    <manufacturerSrn>GB-MF-000035140</manufacturerSrn>
    <authorisedRepresentativeName>Advena Limited</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>MT-AR-000000234</authorisedRepresentativeSrn>
    <riskClass>Sınıf I</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0499</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED GASTROINTESTINAL DEVICES - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ES-CYT-102</reference>
    <placedOnMarketCountry>Sweden</placedOnMarketCountry>
    <lastUpdated>2026-07-31T06:07:07.165Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778108184</udiDi>
    <basicUdiDi>42517781MD347D7</basicUdiDi>
    <tradeName>DulcoSoft</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>795089</reference>
    <placedOnMarketCountry>Ireland</placedOnMarketCountry>
    <lastUpdated>2026-07-30T22:07:42.065Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106234</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1571308</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:38:12.714Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106241</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1571391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.998Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106258</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1571373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.966Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106265</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>572308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.908Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106272</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>572391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.838Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106289</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>572373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.764Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106296</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>573308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.713Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106302</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>573391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.686Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106319</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>573373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.645Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106326</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>574308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.586Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106333</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>574391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.552Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106340</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>574373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.514Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106357</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>314571308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.483Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106364</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>314571391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.451Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106371</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>314571373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.415Z</lastUpdated>
  </row>
</eudamedExport>